The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.
A 46-year-old woman attended our emergency department reporting a 3-month history of dyspnoea and, in the last 2 weeks, lower limb oedema. The patient had a history of rheumatoid arthritis, which had ...
TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C). TN-201 ...